Sanofi (SNY)
(Delayed Data from NSDQ)
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $51.22 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.20 USD
+0.77 (1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $51.22 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Zacks News
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $51.54 in the latest trading session, marking a +1.3% move from the prior day.
GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
by Zacks Equity Research
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $51.01 in the latest trading session, marking a +1.09% move from the prior day.
Pharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
by Kinjel Shah
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
The Zacks Analyst Blog Highlights Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge
by Zacks Equity Research
Fomento Economico Mexicano, NextEra Energy, Sanofi, NVIDIA and Enbridge are included in this Analyst Blog.
Top Stock Reports for FEMSA, NextEra Energy & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).
Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal
by Zacks Equity Research
Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
by Zacks Equity Research
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.
Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote
by Zacks Equity Research
The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.
SNY or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. LLY: Which Stock Is the Better Value Option?
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study
by Kinjel Shah
Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.
Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised
by Zacks Equity Research
Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
Sanofi (SNY) Q1 Earnings Beat, Sales Miss, Dupixent Strong
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings but misses the same for sales. Higher sales of Dupixent and rare disease drugs drive Specialty Care GBU sales.